{"id":"W2099259685","doi":"10.1093/annonc/mdi310","title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":301,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bayer (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Toxicity; Adverse effect; Kinase; Internal medicine; Bay; Pharmacology; Refractory (planetary science); Tyrosine-kinase inhibitor; Cancer; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002912397,0.0001708727,0.0003171094,0.00004814798,0.00005922542,0.000004622375,0.0001853889,0.00007577128,0.00000313869],"category_scores_gemma":[0.0001434681,0.0001074131,0.00004265171,0.0000705299,0.0001473673,0.00000685259,0.0001606302,0.00009227706,2.513961e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000101974,"about_ca_system_score_gemma":0.00009299443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003487119,"about_ca_topic_score_gemma":0.000121368,"domain_scores_codex":[0.9988721,0.00009139609,0.0003943442,0.000303228,0.000115812,0.0002231021],"domain_scores_gemma":[0.9991086,0.00009369328,0.0002445798,0.000322197,0.0001464559,0.00008452741],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02525821,0.01440181,0.01714834,0.0001390934,0.0002100123,0.00001095348,0.002436272,0.0002442628,0.6419104,0.0000510268,0.001381948,0.2968077],"study_design_scores_gemma":[0.03674895,0.09747826,0.08194674,0.0001263192,0.0001145428,0.00001382639,0.0008243746,0.0001463687,0.6124875,0.00001223736,0.1696318,0.0004691409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976037,0.0001817553,0.00003998737,0.0005757836,0.00009004283,0.001077362,0.0002175262,0.000002340414,0.0002115672],"genre_scores_gemma":[0.9983802,0.00008721308,0.000291011,0.001007855,0.0001003409,0.00003641596,0.00002739199,0.00001786578,0.00005165176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2963386,"threshold_uncertainty_score":0.4380178,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03243005053116366,"score_gpt":0.3398462573339467,"score_spread":0.307416206802783,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}